2017 Form 10-K Financial Statement

#000119312518117053 Filed on April 13, 2018

View on sec.gov

Income Statement

Concept 2017 2016 Q4 2016
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $15.09M -$4.900M $4.593M
YoY Change 228.52% -278.83% -56.71%
% of Gross Profit
Research & Development $6.067M -$3.850M $11.40M
YoY Change -46.76% -179.38% -51.74%
% of Gross Profit
Depreciation & Amortization $260.0K -$100.0K $3.000K
YoY Change 8566.67% -47.37% -97.2%
% of Gross Profit
Operating Expenses $21.16M -$8.740M $31.87M
YoY Change -33.61% -215.15% -6.88%
Operating Profit -$23.04M -$15.99M
YoY Change 44.1% -53.28%
Interest Expense -$460.0K -$13.35M -$1.170M
YoY Change -60.68% -770.85% -392.5%
% of Operating Profit
Other Income/Expense, Net -$23.50M -$5.710M $21.01M
YoY Change -211.86% -1397.73% -580.65%
Pretax Income -$23.50M -$8.510M -$17.68M
YoY Change 32.92% -18.49% -54.19%
Income Tax $253.0K $0.00 $1.000K
% Of Pretax Income
Net Earnings -$23.75M $350.0K -$17.68M
YoY Change 34.35% -101.78% -72.33%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$475.0M $5.833M -$884.0M
COMMON SHARES
Basic Shares Outstanding 217.0M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 2016 Q4 2016
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.320M $6.000M $5.960M
YoY Change -61.07% -79.8% -79.95%
Cash & Equivalents $2.320M $5.962M $5.960M
Short-Term Investments
Other Short-Term Assets $10.77M $400.0K $420.0K
YoY Change 2464.29% -98.33% -98.24%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $13.09M $6.379M $6.380M
YoY Change 105.17% -88.1% -88.1%
LONG-TERM ASSETS
Property, Plant & Equipment $199.0K
YoY Change -40.6%
Goodwill $5.898M
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $930.0K $0.00 $40.00K
YoY Change 2225.0% -100.0% -76.47%
Total Long-Term Assets $20.44M $41.00K $40.00K
YoY Change 51000.0% -99.86% -99.86%
TOTAL ASSETS
Total Short-Term Assets $13.09M $6.379M $6.380M
Total Long-Term Assets $20.44M $41.00K $40.00K
Total Assets $33.53M $6.420M $6.420M
YoY Change 422.27% -92.18% -92.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $11.69M $840.0K $0.00
YoY Change -47.4% -100.0%
Accrued Expenses $2.790M $4.049M $3.820M
YoY Change -26.96% -23.49% -27.79%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $8.380M $16.40M $1.710M
YoY Change 390.06% 246.0% -63.92%
Total Short-Term Liabilities $24.57M $5.758M $5.760M
YoY Change 326.56% -89.91% -89.91%
LONG-TERM LIABILITIES
Long-Term Debt $2.610M $5.700M $5.660M
YoY Change -53.89%
Other Long-Term Liabilities $2.600M $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Liabilities $5.210M $5.700M $5.660M
YoY Change -7.95% -7.82%
TOTAL LIABILITIES
Total Short-Term Liabilities $24.57M $5.758M $5.760M
Total Long-Term Liabilities $5.210M $5.700M $5.660M
Total Liabilities $31.46M $11.42M $11.42M
YoY Change 175.48% -83.36% -83.36%
SHAREHOLDERS EQUITY
Retained Earnings -$30.43M
YoY Change
Common Stock $25.44M
YoY Change -91.43%
Preferred Stock
YoY Change
Treasury Stock (at cost) $3.849M
YoY Change 0.0%
Treasury Stock Shares 33.75K shares
Shareholders Equity $2.070M -$4.997M -$5.000M
YoY Change
Total Liabilities & Shareholders Equity $33.53M $6.420M $6.420M
YoY Change 422.27% -92.18% -92.18%

Cashflow Statement

Concept 2017 2016 Q4 2016
OPERATING ACTIVITIES
Net Income -$23.75M $350.0K -$17.68M
YoY Change 34.35% -101.78% -72.33%
Depreciation, Depletion And Amortization $260.0K -$100.0K $3.000K
YoY Change 8566.67% -47.37% -97.2%
Cash From Operating Activities -$10.99M $25.07M -$11.85M
YoY Change -7.27% -264.07% -75.39%
INVESTING ACTIVITIES
Capital Expenditures $6.000K
YoY Change -96.08%
Acquisitions
YoY Change
Other Investing Activities $12.16M $960.0K -$90.00K
YoY Change -13611.11% -91.5% -100.85%
Cash From Investing Activities $12.16M $970.0K -$85.00K
YoY Change -14403.53% -91.35% -100.82%
FINANCING ACTIVITIES
Cash Dividend Paid $0.00
YoY Change
Common Stock Issuance & Retirement, Net $6.007M $33.53M
YoY Change -82.09% -29.28%
Debt Paid & Issued, Net $473.0K $5.579M
YoY Change -91.52% 42.65%
Cash From Financing Activities $5.534M -16.26M 16.50M
YoY Change -66.46% 1526.0% -62.37%
NET CHANGE
Cash From Operating Activities -$10.99M 25.07M -11.85M
Cash From Investing Activities $12.16M 970.0K -85.00K
Cash From Financing Activities $5.534M -16.26M 16.50M
Net Change In Cash $6.703M 9.780M 4.565M
YoY Change 46.83% -293.28% -24.92%
FREE CASH FLOW
Cash From Operating Activities -$10.99M $25.07M -$11.85M
Capital Expenditures $6.000K
Free Cash Flow -$11.86M
YoY Change -75.46%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
6572542 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1268489 shares
CY2017Q2 dei Entity Public Float
EntityPublicFloat
21640272
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1397000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
-12262000
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4049000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
6379000
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1077000
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
25434000
CY2016Q4 us-gaap Assets
Assets
6420000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5962000
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000 shares
CY2016Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0 shares
CY2016Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
1709000
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1268489 shares
CY2016Q4 us-gaap Convertible Debt
ConvertibleDebt
7368000
CY2016Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
5659000
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
3549000
CY2016Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
41000
CY2016Q4 us-gaap Deferred Tax Assets Other Tax Carryforwards
DeferredTaxAssetsOtherTaxCarryforwards
81000
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
3145000
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
295000
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
3508000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
28000
CY2016Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
41000
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
249000
CY2016Q4 us-gaap Liabilities
Liabilities
11417000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6420000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5758000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
227000
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
332000
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
85000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-30431000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
55000 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
52.94
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
-4997000
CY2016Q4 sls Contract Research Payable
ContractResearchPayable
2496000
CY2016Q4 sls Impact On Tax Provision From Unrecognized Tax Benefits
ImpactOnTaxProvisionFromUnrecognizedTaxBenefits
44000
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5766891 shares
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Minority Interest Ownership Percentage By Noncontrolling Owners
MinorityInterestOwnershipPercentageByNoncontrollingOwners
0.325 pure
CY2017Q4 us-gaap Minority Interest Ownership Percentage By Parent
MinorityInterestOwnershipPercentageByParent
0.675 pure
CY2017Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
14900000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3201000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
13087000
CY2017Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
11907000
CY2017Q4 us-gaap Accrued Exchange Fee Rebate Current
AccruedExchangeFeeRebateCurrent
223000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1744000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
56254000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
11691000
CY2017Q4 us-gaap Assets
Assets
33526000
CY2017Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
1294000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2319000
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5766891 shares
CY2017Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
1662000
CY2017Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
963000 shares
CY2017Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
1619000 shares
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5766891 shares
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2017Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
3438000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
6423000
CY2017Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1765000
CY2017Q4 us-gaap Deferred Tax Assets Other Tax Carryforwards
DeferredTaxAssetsOtherTaxCarryforwards
395000
CY2017Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
10200000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
1028000
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
345000
CY2017Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
1673000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
3700000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
4658000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
3700000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2550000
CY2017Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
3438000
CY2017Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
925000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
566000
CY2017Q4 us-gaap Goodwill
Goodwill
1914000
CY2017Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
17600000
CY2017Q4 us-gaap Interest Receivable
InterestReceivable
800000
CY2017Q4 us-gaap Liabilities
Liabilities
31456000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
33526000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
24569000
CY2017Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
2603000
CY2017Q4 us-gaap Long Term Debt
LongTermDebt
10988000
CY2017Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
8377000
CY2017Q4 us-gaap Litigation Reserve Current
LitigationReserveCurrent
1300000
CY2017Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2611000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
191000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
299000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
76000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
223000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
337000
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
10431000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-54185000
CY2017Q4 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
7.86
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
10000 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1240.55
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10000 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1240.55
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
2070000
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
72000
CY2017Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
426000
CY2017Q4 sls Contingent Purchase Price Consideration Net Of Current Portion
ContingentPurchasePriceConsiderationNetOfCurrentPortion
1294000
CY2017Q4 sls Fair Value Of Warrants Potentially Settleable In Cash
FairValueOfWarrantsPotentiallySettleableInCash
1309000
CY2017Q4 sls Warrant Liability
WarrantLiability
1309000
CY2017Q4 sls Share Based Compensation Arrangement By Share Based Payment Award Options Canceled Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledIntrinsicValue
0
CY2017Q4 sls Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAggregateIntrinsicValue
0
CY2017Q4 sls Deferred Tax Assets Licensing Deduction Deferral
DeferredTaxAssetsLicensingDeductionDeferral
2105000
CY2017Q4 sls Restricted Cash And Cash Equivalents Fair Value Disclosure
RestrictedCashAndCashEquivalentsFairValueDisclosure
10245000
CY2017Q4 sls Deferred Tax Asset Net Operating Loss Carryforwards Indefinite Life
DeferredTaxAssetNetOperatingLossCarryforwardsIndefiniteLife
1800000
CY2017Q4 sls Fair Value Of Warrants Liabilities
FairValueOfWarrantsLiabilities
1309000
CY2017Q4 sls Number Of Stock Options Granted
NumberOfStockOptionsGranted
0 Option
CY2017Q4 sls Contract Research Payable
ContractResearchPayable
51000
CY2017Q4 sls Debt Instrument Covenant Prepay Lesser Accrued And Unpaid Interest
DebtInstrumentCovenantPrepayLesserAccruedAndUnpaidInterest
18500000
CY2017Q4 sls Impact On Tax Provision From Unrecognized Tax Benefits
ImpactOnTaxProvisionFromUnrecognizedTaxBenefits
28000
CY2017 dei Amendment Flag
AmendmentFlag
false
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3169000
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
986 shares
CY2017 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3169000
CY2017 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
24089000
CY2017 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
0
CY2017 us-gaap Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
12519000
CY2017 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <i>Concentration of Credit Risk</i></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions, the balances of which frequently exceed federally insured limits.</p> </div>
CY2017 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2017 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
39000
CY2017 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
39000
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-10.44
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.011 pure
CY2017 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
1812000
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3643000
CY2017 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
76000
CY2017 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
0
CY2017 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
214000
CY2017 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
138000
CY2017 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
0
CY2017 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2017 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017 dei Document Type
DocumentType
10-K
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.001 pure
CY2017 dei Document Period End Date
DocumentPeriodEndDate
2017-12-31
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.004 pure
CY2017 dei Entity Registrant Name
EntityRegistrantName
SELLAS LIFE SCIENCES GROUP, INC.
CY2017 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2017 dei Entity Central Index Key
EntityCentralIndexKey
0001390478
CY2017 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.003 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.344 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.002 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.014 pure
CY2017 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2017 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2017 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
1914000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
265000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-23501000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-23766000
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2374000
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
253000
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
8366000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-73000
CY2017 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-462000
CY2017 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
941000
CY2017 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
200000
CY2017 us-gaap Litigation Settlement Amount Awarded From Other Party
LitigationSettlementAmountAwardedFromOtherParty
1300000
CY2017 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-24429000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1812000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5534000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10989000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-23754000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-23039000
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6007000
CY2017 us-gaap Production Related Impairments Or Charges
ProductionRelatedImpairmentsOrCharges
5200000
CY2017 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
473000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6067000
CY2017 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
449000
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
52.94
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1240.55
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
3169000
CY2017 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
15089000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
55000 shares
CY2017 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
12487000
CY2017 us-gaap Severance Costs1
SeveranceCosts1
1883000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
10000 shares
CY2017 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.03 pure
CY2017 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
1294000
CY2017 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
Immediately prior to the Merger, the Galena effected a 1-for-30 reverse stock split of the Company’s outstanding common stock.
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6007000
CY2017 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
28000
CY2017 dei Trading Symbol
TradingSymbol
SLS
CY2017 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
44000
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2340368 shares
CY2017 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
1200000
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <i>Use of Estimates</i></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> The preparation of these consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> On an ongoing basis, the Company evaluates its estimates using historical experience and other factors, including the current economic environment. Significant items subject to such estimates are assumptions used for purposes of determining stock-based compensation, the fair value of the warrants, beneficial conversion features associated with convertible notes, fair value of intangible assets acquired, carrying value of goodwill, fair value of contingent purchase price consideration, fair value of deferred tax liability assumed and accounting for research and development activities. Management believes its estimates to be reasonable under the circumstances. Actual results could differ significantly from those estimates.</p> </div>
CY2017 sls Litigation Settlement Amount Cash
LitigationSettlementAmountCash
50000
CY2017 sls Non Cash Research And Development Expense
NonCashResearchAndDevelopmentExpense
258000
CY2017 sls Change In Fair Value Of Warrant Liabilities
ChangeInFairValueOfWarrantLiabilities
0
CY2017 sls Fair Value Of Warrants Exercised
FairValueOfWarrantsExercised
1309000
CY2017 sls Class Of Warrant Or Right Granted
ClassOfWarrantOrRightGranted
316000 shares
CY2017 sls Class Of Warrant Or Right Expired
ClassOfWarrantOrRightExpired
0 shares
CY2017 sls Class Of Warrant Or Right Assumed In Acquisition
ClassOfWarrantOrRightAssumedInAcquisition
647000 shares
CY2017 sls Operating Loss Carryforwards Expiration Year Range Start
OperatingLossCarryforwardsExpirationYearRangeStart
2027
CY2017 sls Operating Loss Carryforwards Expiration Year Range End
OperatingLossCarryforwardsExpirationYearRangeEnd
2027
CY2017 sls Business Acquisition Pro Forma Earnings Per Share Basic And Diluted
BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted
5.15
CY2017 sls Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
0.011 pure
CY2017 sls Fair Valueof Warrants Granted
FairValueofWarrantsGranted
0
CY2017 sls Issuanceof Common Stockfor Litigation Settlement
IssuanceofCommonStockforLitigationSettlement
1250000
CY2017 sls Shares Issued In Connection With Acquisition
SharesIssuedInConnectionWithAcquisition
12487000
CY2017 sls Fair Value Of Stock Options Assumed In Connection With Acquisition
FairValueOfStockOptionsAssumedInConnectionWithAcquisition
32000
CY2017 sls Stock Issued In Connection With Amendments To License During Period Value
StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodValue
388000
CY2017 sls Stock Issued During Period Value Settlement Of Related Party Accounts Payable
StockIssuedDuringPeriodValueSettlementOfRelatedPartyAccountsPayable
378000
CY2017 sls Stock Issued For Anti Dilution Provisions
StockIssuedForAntiDilutionProvisions
61000
CY2017 sls Stock Issued For Incentive Fee Payment In Connection With Acquisition During Period
StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod
941000
CY2017 sls Shares And Common Stock Warrants Issued Upon Conversion Of Notes During Period
SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriod
6739000
CY2017 sls Business Combination Pro Forma Transaction Costs
BusinessCombinationProFormaTransactionCosts
8700000
CY2017 sls Business Combination Fair Value Of Shares Outstanding
BusinessCombinationFairValueOfSharesOutstanding
12487000
CY2017 sls Business Combination Estimated Fair Value Of Stock Options Outstanding
BusinessCombinationEstimatedFairValueOfStockOptionsOutstanding
32000
CY2017 sls Adjustments To Additional Paid In Capital Stock Options Exercised In Connection With Acquisition
AdjustmentsToAdditionalPaidInCapitalStockOptionsExercisedInConnectionWithAcquisition
32000
CY2017 sls Shares Issued To Settler Elated Party Accounts Payable
SharesIssuedToSettlerElatedPartyAccountsPayable
228000
CY2017 sls Shares Issued To Settle Accounts Payable
SharesIssuedToSettleAccountsPayable
150000
CY2017 sls Deemed Dividend Associated With Conversion Of Note And Common Stock Warrant Issuance
DeemedDividendAssociatedWithConversionOfNoteAndCommonStockWarrantIssuance
675000
CY2017 sls Operating Loss And Tax Credit Carryforwards Limitations On Use Minimum Change In Ownership Percentage
OperatingLossAndTaxCreditCarryforwardsLimitationsOnUseMinimumChangeInOwnershipPercentage
0.50 pure
CY2017 sls Maximum Indefinitelived Deferred Tax Liability As Percentage Of Net Operating Loss
MaximumIndefinitelivedDeferredTaxLiabilityAsPercentageOfNetOperatingLoss
0.80 pure
CY2017 sls Operating Loss And Tax Credit Carryforwards Limitations On Use Period Of Ownership Percentage
OperatingLossAndTaxCreditCarryforwardsLimitationsOnUsePeriodOfOwnershipPercentage
P3Y
CY2017 sls Deemed Dividend On Debt Conversion
DeemedDividendOnDebtConversion
675000
CY2017 sls Adjustments To Additional Paid In Capital Deemed Dividend On Debt Conversion
AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnDebtConversion
-675000
CY2017 sls Sharebased Compensation Arrangement By Sharebased Payment Award Options Assumed In Acquisition Grant Date Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAssumedInAcquisitionGrantDateIntrinsicValue
0
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
354000
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
122 shares
CY2016 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
354000
CY2016 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
28389000
CY2016 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
0
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
4565000
CY2016 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
0
CY2016 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-85000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
16500000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11850000
CY2016 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
42000
CY2016 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
42000
CY2016 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
0
CY2016 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-41000
CY2016 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2016 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-41000
CY2016 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-41000
CY2016 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3000
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-18.66
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.104 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.255 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.020 pure
CY2016 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-201000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
108000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17680000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-17788000
CY2016 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1830000
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
477000
CY2016 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
85000
CY2016 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-1166000
CY2016 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
200000
CY2016 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17681000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-17681000
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-15988000
CY2016 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
526000
CY2016 us-gaap Paid In Kind Interest
PaidInKindInterest
1166000
CY2016 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
15000000
CY2016 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
1500000
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11395000
CY2016 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
1974000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
354000
CY2016 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4593000
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
38.03
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
52.94
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
0
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
55000 shares
CY2016 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
15411000
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
947401 shares
CY2016 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
1800000
CY2016 sls Non Cash Research And Development Expense
NonCashResearchAndDevelopmentExpense
821000
CY2016 sls Stock Issued During Period Value License Agreement
StockIssuedDuringPeriodValueLicenseAgreement
1976000
CY2016 sls Business Acquisition Pro Forma Earnings Per Share Basic And Diluted
BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted
8.61
CY2016 sls Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
0.001 pure
CY2016 sls Stock Issued During Period Value Partial Consideration Of License Fee
StockIssuedDuringPeriodValuePartialConsiderationOfLicenseFee
900000
CY2016 sls Stock Issued In Cancellation Of License Agreement During Period Value
StockIssuedInCancellationOfLicenseAgreementDuringPeriodValue
502000
CY2016 sls Stock Issued During Period Value Cancellation Of Long Term Debt
StockIssuedDuringPeriodValueCancellationOfLongTermDebt
5803000

Files In Submission

Name View Source Status
0001193125-18-117053-index-headers.html Edgar Link pending
0001193125-18-117053-index.html Edgar Link pending
0001193125-18-117053.txt Edgar Link pending
0001193125-18-117053-xbrl.zip Edgar Link pending
d556278d10k.htm Edgar Link pending
d556278dex102.htm Edgar Link pending
d556278dex103.htm Edgar Link pending
d556278dex1073.htm Edgar Link pending
d556278dex1074.htm Edgar Link pending
d556278dex1075.htm Edgar Link pending
d556278dex1076.htm Edgar Link pending
d556278dex1077.htm Edgar Link pending
d556278dex1078.htm Edgar Link pending
d556278dex1079.htm Edgar Link pending
d556278dex1080.htm Edgar Link pending
d556278dex1081.htm Edgar Link pending
d556278dex1082.htm Edgar Link pending
d556278dex1083.htm Edgar Link pending
d556278dex1084.htm Edgar Link pending
d556278dex1085.htm Edgar Link pending
d556278dex1086.htm Edgar Link pending
d556278dex1087.htm Edgar Link pending
d556278dex109.htm Edgar Link pending
d556278dex211.htm Edgar Link pending
d556278dex231.htm Edgar Link pending
d556278dex232.htm Edgar Link pending
d556278dex31.htm Edgar Link pending
d556278dex311.htm Edgar Link pending
d556278dex312.htm Edgar Link pending
d556278dex321.htm Edgar Link pending
d556278dex41.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g556278001.jpg Edgar Link pending
g556278002.jpg Edgar Link pending
g556278003.jpg Edgar Link pending
g556278004.jpg Edgar Link pending
g556278005.jpg Edgar Link pending
g556278dsp073.jpg Edgar Link pending
g556278dsp074.jpg Edgar Link pending
g556278dsp1a.jpg Edgar Link pending
g556278dsp1b.jpg Edgar Link pending
g556278g0327071551902.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
sls-20171231.xml Edgar Link completed
sls-20171231.xsd Edgar Link pending
sls-20171231_cal.xml Edgar Link unprocessable
sls-20171231_def.xml Edgar Link unprocessable
sls-20171231_lab.xml Edgar Link unprocessable
sls-20171231_pre.xml Edgar Link unprocessable